Tinengotinib
- Generic Name
- Tinengotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19ClN6O
- CAS Number
- 2230490-29-4
- Unique Ingredient Identifier
- WZ9TJ0L9Y8
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06457919
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- TransThera Sciences (Nanjing), Inc.
- Registration Number
- NCT06370013
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath